These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 22691169

  • 1. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study.
    Ahern T, Tobin AM, Corrigan M, Hogan A, Sweeney C, Kirby B, O'Shea D.
    J Eur Acad Dermatol Venereol; 2013 Nov; 27(11):1440-3. PubMed ID: 22691169
    [Abstract] [Full Text] [Related]

  • 2. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.
    Hogan AE, Tobin AM, Ahern T, Corrigan MA, Gaoatswe G, Jackson R, O'Reilly V, Lynch L, Doherty DG, Moynagh PN, Kirby B, O'Connell J, O'Shea D.
    Diabetologia; 2011 Nov; 54(11):2745-54. PubMed ID: 21744074
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study.
    Xu X, Lin L, Chen P, Yu Y, Chen S, Chen X, Shao Z.
    Diabetes Res Clin Pract; 2019 Apr; 150():167-173. PubMed ID: 30844468
    [Abstract] [Full Text] [Related]

  • 6. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial.
    Faurschou A, Gyldenløve M, Rohde U, Thyssen JP, Zachariae C, Skov L, Knop FK, Vilsbøll T.
    J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):555-9. PubMed ID: 25139195
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies.
    Chang G, Chen B, Zhang L.
    J Dermatolog Treat; 2022 May; 33(3):1299-1305. PubMed ID: 33934692
    [Abstract] [Full Text] [Related]

  • 8. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction.
    Pastel E, McCulloch LJ, Ward R, Joshi S, Gooding KM, Shore AC, Kos K.
    Clin Sci (Lond); 2017 Mar 01; 131(5):343-353. PubMed ID: 28049736
    [Abstract] [Full Text] [Related]

  • 9. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.
    Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J, NN2211-1499 Study Group.
    Exp Clin Endocrinol Diabetes; 2006 Sep 01; 114(8):417-23. PubMed ID: 17039422
    [Abstract] [Full Text] [Related]

  • 10. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
    Flint A, Kapitza C, Hindsberger C, Zdravkovic M.
    Adv Ther; 2011 Mar 01; 28(3):213-26. PubMed ID: 21340616
    [Abstract] [Full Text] [Related]

  • 11. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H, Hartmann B, Holst JJ, Viby NE, Hansen LS, Rosenkilde MM, Hare KJ, Poulsen SS.
    Regul Pept; 2012 Nov 10; 179(1-3):91-100. PubMed ID: 22989472
    [Abstract] [Full Text] [Related]

  • 12. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E, Sesti G.
    Clin Ther; 2009 Nov 10; 31(11):2472-88. PubMed ID: 20109994
    [Abstract] [Full Text] [Related]

  • 13. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.
    Davies MJ, Kela R, Khunti K.
    Diabetes Obes Metab; 2011 Mar 10; 13(3):207-20. PubMed ID: 21205109
    [Abstract] [Full Text] [Related]

  • 14. Effects of liraglutide among patients living with psoriasis and obesity.
    Nicolau J, Nadal A, Sanchís P, Pujol A, Nadal C, Masmiquel L.
    Med Clin (Barc); 2023 Oct 13; 161(7):293-296. PubMed ID: 37474395
    [Abstract] [Full Text] [Related]

  • 15. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial.
    Lin L, Xu X, Yu Y, Ye H, He X, Chen S, Chen X, Shao Z, Chen P.
    J Dermatolog Treat; 2022 May 13; 33(3):1428-1434. PubMed ID: 32962477
    [Abstract] [Full Text] [Related]

  • 16. Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance.
    Porter DW, Kerr BD, Flatt PR, Holscher C, Gault VA.
    Diabetes Obes Metab; 2010 Oct 13; 12(10):891-9. PubMed ID: 20920042
    [Abstract] [Full Text] [Related]

  • 17. [Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].
    Jahn E, Sausele T.
    Med Monatsschr Pharm; 2009 Nov 13; 32(11):402-7. PubMed ID: 19947303
    [Abstract] [Full Text] [Related]

  • 18. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B, Bonnard C, Renard E.
    Diabetes Metab; 2011 Dec 13; 37(6):477-88. PubMed ID: 21871831
    [Abstract] [Full Text] [Related]

  • 19. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L, Montanya E.
    Diabetes Obes Metab; 2012 Apr 13; 14 Suppl 2():20-32. PubMed ID: 22405266
    [Abstract] [Full Text] [Related]

  • 20. Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.
    Vilsbøll T, Garber AJ.
    Diabetes Obes Metab; 2012 Apr 13; 14 Suppl 2():41-9. PubMed ID: 22405268
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.